Oligodendroglioma natural history, complications, and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 24: | Line 24: | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Neurosurgery]] | [[Category:Neurosurgery]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Revision as of 20:18, 26 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma natural history, complications, and prognosis On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma natural history, complications, and prognosis |
|
FDA on Oligodendroglioma natural history, complications, and prognosis |
|
CDC on Oligodendroglioma natural history, complications, and prognosis |
|
Oligodendroglioma natural history, complications, and prognosis in the news |
|
Blogs on Oligodendroglioma natural history, complications, and prognosis |
Overview
Natural history
Complications
Prognosis
Oligodendrogliomas are generally felt to be incurable using current treatments. However compared to the more common astrocytomas, they are slowly growing with prolonged survival. In one series, median survival times for oligodendrogliomas were 11.6 years for grade II and 3.5 years for grade III.[1]
Long-term survival is reported in a minority of patients.[2] With aggressive treatment and close monitoring, it is possible to outlive the typical life expectancies for both low grade and high grade oligodendrogliomas. In rare cases, patients have survived for up to fifteen years post-diagnosis. Westergaard’s study (1997) showed that patients younger than 20 years had a median survival of 17.5 years.[3] Another study shows a 34% survival rate after 20 years. [4]
References
- ↑ Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89. PMID: 15977639
- ↑ Tatter SB. Recurrent malignant glioma in adults. Curr Treat Options Oncol. 2002 Dec;3(6):509-24. PMID: 12392640,
- ↑ Herbert H. Engelhard, M.D., Ph.D., Ana Stelea, M.D., and Arno Mundt, M.D.[1] p.449
- ↑ Feigenberg SJ, Amdur RJ, Morris CG, Mendenhall WM, Marcus RB, Friedman WA (2003). "Oligodendroglioma: does deferring treatment compromise outcome?". Am. J. Clin. Oncol. 26 (3): e60–6. doi:10.1097/01.COC.0000072507.25834.D6. PMID 12796617.